Hospitals surveillance techniques for central-lineassociated bloodstream infections may vary so much that attempts to compare the results among medical centers are likely to be inaccurate, according to a Nov. 10 .
Although the use of early hemodialysis in relatively young and healthy end-stage renal disease patients has more than doubled since 1996, that practice may have increased their 1-year mortality risk, new research suggests.
Patients with atrial fibrillation who were taking the anticoagulant dabigatran for secondary stroke prevention suffered an ischemic stroke or systemic embolism at a rate similar to patients taking warfarin in a prespecified subgroup analysis of patients from the 2-year RE-LY trial.
Phase II trial data confirm that an experimental BRAF inhibitor dramatically shrinks tumors and extends time to disease progression in patients with previously treated BRAF V600 mutationpositive metastatic melanoma, according to a report presented Nov. 5 at the seventh international congress of the Society for Melanoma Research in Sydney.
A double-blind, randomized, placebo-controlled trial of the cholinesterase-inhibiting drug rivastigmine was halted prematurely when it was shown to be ineffective and potentially fatal for critical care patients experiencing delirium, according to a report in the Nov. 5 issue of the Lancet.
GAITHERSBURG, Md. (EGMN) Intravenous phenytoin should continue to be marketed but with revisions to its label that include more information about the risk of purple glove syndrome associated with its use, advisors to the Food and Drug Administration recommended on Nov. 3.
Illnesses and injuries requiring hospitalization of elderly people usually increase the patients level of disability, regardless of what that level was prior to the event, according to a report in the Nov. 3 issue of JAMA.
Reducing or eliminating copayments for medications to treat common chronic conditions can improve medication adherence by several percentage points, according to a study published Nov. 2 in the journal Health Affairs.
Ceftaroline, an intravenous cephalosporin antibiotic, has been approved for treating community- acquired bacterial pneumonia and for acute bacterial skin and skin structure infections, including methicillin-resistant , the Food and Drug Administration announced on Oct. 29.
Lurasidone, an atypical antipsychotic, has been approved for treating adults with schizophrenia, the Food and Drug Administration announced Oct. 28.
